Selank research and evidence overview

Selank is unusual among catalogue peptides in that a controlled human study actually exists — one 62-patient Russian comparison against a benzodiazepine, published in 2008 in a Russian-language psychiatry journal. That is more than most peptides sold alongside it can claim, and far less than the phrase "clinically proven anxiolytic" implies. There is no large multinational trial, no regulatory approval outside Russia and neighbouring markets, and no independent replication in English-language literature.

Zozulia and colleagues studied 62 patients with generalized anxiety disorder and neurasthenia, comparing selank (30 patients) with the benzodiazepine medazepam (32 patients), with symptoms rated on the Hamilton, Zung, and CGI scales (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008; PubMed 18454096). The reported anxiolytic effects of the two drugs were similar, with selank additionally described as having antiasthenic and psychostimulant effects.

The study also measured enkephalin activity in serum: patients with these diagnoses had a reduced half-life of leu-enkephalin that correlated with illness duration and symptom severity, and that parameter increased during selank treatment. This is the source of the "Selank works through the enkephalin system" claim — a biochemical correlation within a small trial, not a demonstrated mechanism of clinical benefit.

Around that single trial sits a body of Russian laboratory and animal research, largely from the Institute of Molecular Genetics and collaborating groups, examining anxiety-like and stress behaviour in rodents, effects on GABAergic and serotonergic signalling, and changes in neurotrophic factors such as BDNF. Selank is a synthetic analogue of the immunomodulatory peptide tuftsin with a proline-glycine-proline tail added for stability, and much of this work concerns how that stabilisation changes its central activity. The preclinical literature is coherent and points toward plausible mechanisms; it does not substitute for clinical evidence.

A related asymmetry is worth noting: Selank was developed and registered as a medicine within one regulatory system, and the trial above was designed to support that registration. No FDA or EMA authorisation exists, no multinational phase 3 programme has been run, and no independent group outside that tradition has published a replication attempt in the two decades since. Absence of replication is not evidence of failure — it usually means nobody with funding has tried.

• Blinding and control. The published abstract describes an active comparator, not a placebo arm, so the size of a placebo response in this population is unknown.
• Language and indexing. The full methods exist in Russian only; the international record is an abstract, which limits outside appraisal of randomisation and analysis.
• Population. Patients carried clinical diagnoses of GAD or neurasthenia. Nothing here addresses subclinical stress, focus, or performance in healthy adults.
• Route. Clinical use in Russia is intranasal. Injectable products sold internationally are not the formulation studied.
• Duration. Short treatment courses say nothing about long-term use, tolerance, or discontinuation.

A recurring pitfall is treating a favourable comparison with an existing anxiolytic as if it settled the question. One 62-patient open comparison in a single country is a starting point for inquiry, not a substitute for large, independent, controlled trials.